Form 4: Trevi Therapeutics CEO Jennifer Good Executes Stock Option and Sells Shares

Jennifer Good, CEO of Trevi Therapeutics, exercised stock options and sold shares of common stock on September 6 and September 9, 2024.

Summary

• Jennifer Good, the President and CEO of Trevi Therapeutics, exercised stock options to acquire shares of common stock and subsequently sold a portion of those shares.
• On September 6, 2024, she exercised options for 4,219 shares at a price of $1.43 per share and sold the same amount at a weighted average price of $3.0302 per share.
• On September 9, 2024, she exercised options for 1,840 shares at $1.43 per share and sold the same amount at a weighted average price of $3.0362 per share.
• Following these transactions, Ms. Good directly owns 213,313 shares of Trevi Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily reflect a broader industry trend. However, monitoring insider activity can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the overall effect is likely to be minimal given the relatively small number of shares involved.

Key Dates